Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Influence of Control Deprivation on the Use of the Analytical Cognitive Style in Anorexic Subjects

NCT07274722 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-04-04
Last updated
2025-12-10

Condition(s) studied

Anorexia Nervosa

Investigational drug(s) / intervention(s)

Cognitive Control Deprivation Task

Cognitive Control Deprivation Task: The investigators will measure the reaction time to the detection of a stimulus requiring analytical information processing compared with the time required to detect a stimulus requiring global information processing. These measurements will be carried out before and after a cognitive control deprivation experiment, which will be used to activate a need for control in the experimental context. The two measures will then be compared to examine the changes that occur after the deprivation of control.

Study summary

The use of an analytical cognitive style is a specific feature of anorexia nervosa and is thought to contribute to the maintenance of the disorder, in particular by encouraging fragmented body perception and a focus on certain parts of the body to the detriment of overall harmony and coherence. The need for control has also been described as an important element in the pathology. At the same time, some authors have shown that, outside of any pathology, recourse to the analytical cognitive style could respond to a need to restore control and, in turn, improve the feeling of control. However, at present, no causal relationship has been demonstrated between the feeling of loss of control and the analytical cognitive style in anorexia nervosa. However, such a relationship would enable us to gain a better understanding of the underlying mechanisms of the disorder and to better target the treatment of patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Be undergoing treatment at Centre Hospitalier Laborit (CHL) or Centre Hospitalier Universitaire (CHU) de Poitiers for an Eating Disorder (ED) of the Anorexia Nervosa type. * Patients must meet the diagnostic criteria for Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5; American Psychiatric Association, APA, 2013), or present a sub-clinical symptomatology requiring treatment: (A) Restriction of energy intake relative to requirements, leading to a significantly low body weight, taking into account age, sex, developmental stage, and physical health; (B) Intense fear of gaining weight or becoming fat, or persistent behavior that interferes with weight gain, even when at a significantly low weight; (C) Disturbance in the way body weight or shape is experienced, undue influence of body weight or shape on self-esteem, or persistent lack of recognition of the seriousness of the current low body weight. Exclusion Criteria: * Objection of the referring therapist * Currently receiving cognitive remediation targeting mental flexibility and central coherence * Body Mass Index (BMI) less than 14 * Inability to understand instructions in French * Visual impairment or dyslexia

Primary outcome measure(s)

  • Reaction time — Baseline (before cognitive control deprivation) and immediately post-task (after cognitive control deprivation on Day 1)

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier Henri Laborit Poitiers France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07274722 on ClinicalTrials.gov ↗ ← All trials in France